Lee Hyun Woo, Choi Sun Mi, Lee Jinwoo, Park Young Sik, Lee Chang-Hoon, Yoo Chul-Gyu, Kim Young Whan, Han Sung Koo, Lee Sang-Min
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
Acute Crit Care. 2019 Aug;34(3):202-211. doi: 10.4266/acc.2019.00563. Epub 2019 Aug 31.
It has been suggested that a high-flow nasal cannula (HFNC) could help to remove carbon dioxide (CO) from anatomical dead spaces, but evidence to support that is lacking. The objective of this study was to elucidate whether use of an HFNC could reduce the arterial partial pressure of CO (PaCO) in patients with acute hypercapnic respiratory failure who are receiving conventional oxygen (O) therapy.
A propensity score-matched observational study was conducted to evaluate patients treated with an HFNC for acute hypercapnic respiratory failure from 2015 to 2016. The hypercapnia group was defined as patients with a PaCO >50 mm Hg and arterial pH <7.35.
Eighteen patients in the hypercapnia group and 177 patients in the nonhypercapnia group were eligible for the present study. Eighteen patients in each group were matched by propensity score. Decreased PaCO and consequent pH normalization over time occurred in the hypercapnia group (P=0.002 and P=0.005, respectively). The initial PaCO level correlated linearly with PaCO removal after the use of an HFNC (R=0.378, P=0.010). The fraction of inspired O used in the intensive care unit was consistently higher for 48 hours in the nonhypercapnia group. Physiological parameters such as respiratory rate and arterial partial pressure of O improved over time in both groups.
Physiological parameters can improve after the use of an HFNC in patients with acute hypercapnic respiratory failure given low-flow O therapy via a facial mask. Further studies are needed to identify which hypercapnic patients might benefit from an HFNC.
有人提出,高流量鼻导管(HFNC)有助于从解剖学死腔中清除二氧化碳(CO₂),但缺乏支持这一观点的证据。本研究的目的是阐明在接受常规氧(O₂)治疗的急性高碳酸血症呼吸衰竭患者中,使用HFNC是否能降低动脉血二氧化碳分压(PaCO₂)。
进行了一项倾向评分匹配的观察性研究,以评估2015年至2016年接受HFNC治疗急性高碳酸血症呼吸衰竭的患者。高碳酸血症组定义为PaCO₂>50 mmHg且动脉血pH<7.35的患者。
高碳酸血症组18例患者和非高碳酸血症组177例患者符合本研究条件。每组18例患者按倾向评分进行匹配。高碳酸血症组随着时间推移PaCO₂降低且pH随之恢复正常(分别为P = 0.002和P = 0.005)。使用HFNC后,初始PaCO₂水平与PaCO₂清除呈线性相关(R = 0.378,P = 0.010)。非高碳酸血症组在重症监护病房使用的吸入氧分数在48小时内持续较高。两组的呼吸频率和动脉血氧分压等生理参数随时间均有改善。
对于通过面罩接受低流量O₂治疗的急性高碳酸血症呼吸衰竭患者,使用HFNC后生理参数可得到改善。需要进一步研究以确定哪些高碳酸血症患者可能从HFNC中获益。